The company said, “The company is affirming its guidance for the approximately seven-month transition period from May 26 through December 31, 2025. For this transition period, the company expects revenue to be approximately $74 to $76 million, net loss is expected to range from $18.4 million to $16.4 million, and Adjusted EBITDA is expected to be in the range of $12 to $14 million, based on the expectation that Lifecore (LFCR) would exclude for items similar to its historic definition of Adjusted EBITDA. This guidance takes into consideration existing market forces, contracts, and customer order timing, as well as the company’s current beliefs and estimations with respect to success and timing related to growing and diversifying the company’s new business development revenue.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore reports Q3 EPS (29c), consensus (31c)
- Lifecore Biomedical Approves Key Proposals at Annual Meeting
- Lifecore signs agreement with leading global pharmaceutical company
- Lifecore, PolyPeptide collab to offer peptide manufacturing solution
- Lifecore Biomedical, Inc. (LFCR) Q1 Earnings Cheat Sheet
